alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
```

[Federal Register Volume 75, Number 249 (Wednesday, December 29, 2010)]
[Notices]
[Page 82005]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2010-32824]

-----------------------------------------------------------------------

DEPARTMENT OF ENERGY

Proposed Subsequent Arrangement

AGENCY: Office of Nonproliferation and International Security, 
Department of Energy.

ACTION: Proposed subsequent arrangement.

-----------------------------------------------------------------------

SUMMARY: This notice is being issued under the authority of section 
131a. of the Atomic Energy Act of 1954, as amended (42 U.S.C. 2160). 
The Department is providing notice of a proposed subsequent arrangement 
under the Agreement for Cooperation Concerning Civil Uses of Nuclear 
Energy Between the Government of the United States of America and the 
Government of Canada and the Agreement for Cooperation Between the 
United States of America and the Government of the Republic of Korea 
Concerning Civil Uses of Atomic Energy.
    This subsequent arrangement concerns the retransfer of 29,887 kg of 
U.S.-origin natural uranium dioxide (88.00% U), 26,300 kg of which is 
uranium, from Cameco Corporation (Cameco) in Port Hope, Ontario, 
Canada, to Korea Nuclear Fuel Co. Ltd. in Yuson-Gu, Taejon, South 
Korea. The material, which is currently located at Cameco, will be 
transferred for fuel fabrication by Korea Nuclear Fuel Co. Ltd for 
final use in a civilian nuclear reactor power program by Korea Hydro & 
Nuclear Power Co. Ltd. The material was originally obtained by Cameco 
from Crowe Butte Resources pursuant to export license XSOU8798.
    In accordance with section 131a. of the Atomic Energy Act of 1954, 
as amended, it has been determined that this subsequent arrangement 
will not be inimical to the common defense and security.
    This subsequent arrangement will take effect no sooner than January 
13, 2011.

    Dated: December 20, 2010.

    For the Department of Energy.
Thomas P. D'Agostino,
Administrator, National Nuclear Security Administration.
[FR Doc. 2010-32824 Filed 12-28-10; 8:45 am]
BILLING CODE 6450-01-P
```
UNITED STATES GOVERNMENT MEMORANDUM

To: Public Information (MS 5030)

Plans Section, Office of Field 

Operations (MS 5231)

Public Information copy of Exploration Plan

Control # - N-09570

Type - Initial Exploration Plan

Lease(s) - OCS-G07957 Block - 762 Mississippi Canyon Area

OCS-G07962 Block - 762 Mississippi Canyon Area

OCS-G07962 Block - 806 Mississippi Canyon Area

OCS-G24112 Block - 805 Mississippi Canyon Area

Operator - Shell Offshore Inc.

Batch set, drill, and complete wells M-T

DP SEMISUBMERSIBLE

Attached is a copy of the subject plan for public comments on issues that 

should be addressed in an Environmental Assessment.

It has been deemed submitted as of this date and is under review for approval.

James Webb

Plan Coordinator

Description -

Rig Type -

Subject:

From:

June 24, 2011
13 Weeks Ended
                                                     --------------------------
                                                     May 2, 1998    May 3, 1997
                                                     -----------    -----------

     The  computation  of net (loss)  available  & adjusted  shares  outstanding
          follows:

     Net (loss)                                       $ (2,790)      $ (1,361)
     Less:
          Series A preferred stock dividends              (864)          (864)
          Series B preferred stock dividends              (703)          (656)
                                                     --------------------------
A)  Net (loss) used for basic computation            $ (4,357)      $ (2,881)

     Add (where dilutive):
          Series A preferred stock dividends                 -              -
          Series B preferred stock dividends                 -              -
                                                     --------------------------
B)  Net (loss) used for diluted computation          $ (4,357)      $ (2,881)

C)   Weighted average number of common shares
          outstanding, used for basic calculation    4,930,770      4,817,707

     Add (where dilutive) assumed conversion of:
          Series A preferred stock                           -              -
          Series B preferred stock                           -              -
          Stock options                                      -              -
          Warrants for series A preferred stock              -              -
          Warrants for common stock                          -              -
                                                     --------------------------
D)   Adjusted shares outstanding, used for
          fully diluted computation                  4,930,770      4,817,707

     Earnings per share:
          Basic (A divided by C)                       $ (0.88)       $ (0.60)
          Diluted (B divided by D)                     $ (0.88)       $ (0.60)

E)   Extraordinary item                               $ (2,750)           $ -
     Extraordinary item per share (E divided by C)     $ (0.56)           $ -
| 1.   | I have reviewed this Quarterly Report on Form 10-Q of Crimson Exploration Inc.; |
|----------------|---------------------------------------------------------------------------------|

| 2.   | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
|----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 3.   | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
|----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 4.   | The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
|----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 5.   | The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions): |
|----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| Date:  | August 5, 2010                        |   |
|-------------|---------------------------------------|--------|
|        | /s/ Allan D. Keel                     |   |
| Name:       | Allan D. Keel                         |   |
| Title:      | President and Chief Executive Officer |   |
|        |                                  |   |
|        |                                  |   |
```

[Congressional Bills 109th Congress]
[From the U.S. Government Publishing Office]
[H. Res. 93 Introduced in House (IH)]

109th CONGRESS
  1st Session
H. RES. 93

 Providing amounts for the expenses of the Committee on Transportation 
         and Infrastructure in the One Hundred Ninth Congress.

_______________________________________________________________________

                    IN THE HOUSE OF REPRESENTATIVES

                           February 15, 2005

   Mr. Young of Alaska submitted the following resolution; which was 
           referred to the Committee on House Administration

_______________________________________________________________________

                               RESOLUTION

 
 Providing amounts for the expenses of the Committee on Transportation 
         and Infrastructure in the One Hundred Ninth Congress.

    Resolved, 

SECTION 1. AMOUNTS FOR COMMITTEE EXPENSES.

    For the expenses of the Committee on Transportation and 
Infrastructure (hereafter in this resolution referred to as the 
``Committee''), including the expenses of all staff salaries, there 
shall be paid, out of the applicable accounts of the House of 
Representatives for committee salaries and expenses, not more than 
$18,582,105 for the One Hundred Ninth Congress.

SEC. 2. SESSION LIMITATIONS.

    Of the amount specified in section 1--
            (1) not more than $9,007,388 shall be available for 
        expenses incurred during the period beginning at noon on 
        January 3, 2005, and ending immediately before noon on January 
        3, 2006; and
            (2) not more than $9,574,717 shall be available for 
        expenses incurred during the period beginning at noon on 
        January 3, 2006, and ending immediately before noon on January 
        3, 2007.

SEC. 3. VOUCHERS.

    Payments under this resolution shall be made on vouchers authorized 
by the Committee, signed by the Chairman of the Committee, and approved 
in the manner directed by the Committee on House Administration.

SEC. 4. REGULATIONS.

    Amounts made available under this resolution shall be expended in 
accordance with regulations prescribed by the Committee on House 
Administration.
                                 <all>
```
ACCEPTED12-15-00097-CR

TWELFTH COURT OF APPEALSTYLER, TEXAS

5/20/2015 4:22:10 PMCATHY LUSK

CLERK

            FILED IN12th COURT OF APPEALS        TYLER, TEXAS5/20/2015 4:22:10 PM        CATHY S. LUSK                Clerk
§ 516.111 Scope of this subpart. This subpart implements section 572 of the act and provides standards and procedures to establish an index of legally marketed unapproved new animal drugs. This subpart applies only to minor species and not to minor use in major species. This index is only available for new animal drugs intended for use in a minor species for which there is a reasonable certainty that the animal or edible products from the animal will not be consumed by humans or food-producing animals and for new animal drugs intended for use only in a hatchery, tank, pond, or other similar contained man-made structure in an early, nonfood life stage of a food-producing minor species, where safety for humans is demonstrated in accordance with the standard of section 512(d) of the act (including, for an antimicrobial new animal drug, with respect to antimicrobial resistance). The index shall not include a new animal drug that is contained in, or a product of, a transgenic animal. Among its topics, this subpart sets forth the standards and procedures for: ( a ) Investigational exemptions for indexing purposes;
( b ) Submissions to FDA of requests for determination of eligibility of a new animal drug for indexing;
( c ) Establishment and operation of expert panels;
( d ) Submissions to FDA of requests for addition of a new animal drug to the index;
( e ) Modifications to index listings;
( f ) Publication of the index; and
( g ) Records and reports.
```

[Congressional Bills 118th Congress]
[From the U.S. Government Publishing Office]
[H.R. 7377 Enrolled Bill (ENR)]

        H.R.7377

                     One Hundred Eighteenth Congress

                                 of the

                        United States of America

                          AT THE SECOND SESSION

         Begun and held at the City of Washington on Wednesday,
         the third day of January, two thousand and twenty-four

                                 An Act

 
   To amend the Federal Oil and Gas Royalty Management Act of 1982 to 
  improve the management of royalties from oil and gas leases, and for 
                             other purposes.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,
SECTION 1. SHORT TITLE.
    This Act may be cited as the ``Royalty Resiliency Act''.
SEC. 2. DETERMINATION OF ALLOCATIONS OF PRODUCTION FOR UNITS AND 
COMMUNITIZATION AGREEMENTS.
    Section 111(j) of the Federal Oil and Gas Royalty Management Act of 
1982 (30 U.S.C. 1721(j)), as amended by the Federal Oil and Gas Royalty 
Simplification and Fairness Act of 1996 (Public Law 104-185), is 
amended to read as follows:
    ``(j) The Secretary shall issue all determinations of allocations 
of production for units and communitization agreements within 120 days 
of a request for determination. Until the Secretary issues the 
determination, the lessee or its designee of a lease in a unit or 
communitization agreement shall report and pay royalties on oil and gas 
production for each production month in accordance with the terms of 
the proposed allocation of production for the unit or communitization 
agreement. After the Secretary issues the determination, the lessee or 
its designee shall, as necessary, correct such reports and the amount 
of royalties paid on oil and gas production under the unit or 
communitization agreement by not later than the end of the third month 
following the month in which the lessee or its designee receives the 
determination from the Secretary. Subject to the full and timely 
monthly payment of royalties to all parties in accordance with the 
terms of the proposed allocation of production for the unit or 
communitization agreement, the Secretary shall waive interest due on 
obligations subject to the determination until the end of the third 
month following the month in which the lessee or its designee receives 
the determination from the Secretary. This subsection shall not apply 
to unit or communization agreements containing Indian lands.''.

                               Speaker of the House of Representatives.

                            Vice President of the United States and    
                                               President of the Senate.
```
#### § 558.59 Apramycin.

(a) *Specifications.* Type A articles containing 75 grams apramycin (as apramycin sulfate) per pound.

(b) *Sponsor.* See No. 058198 in [§ 510.600(c) of this chapter](/on/2024-09-17/title-21/section-510.600#p-510.600(c)).

(c) *Related tolerances.* See [§ 556.52 of this chapter](/on/2024-09-17/title-21/section-556.52).

(d) *Special considerations.*

(1) Federal law restricts medicated feed containing this veterinary feed directive (VFD) drug to use by or on the order of a licensed veterinarian. See [§ 558.6](/on/2024-09-17/title-21/section-558.6) for additional requirements.

(2) The expiration date of VFDs for apramycin medicated feeds must not exceed 6 months from the date of issuance. VFDs for apramycin shall not be refilled.

(e) *Conditions of use in swine* —

| Apramycin grams/ton | Combination in grams/ton | Indications for use | Limitations | Sponsor |
| --- | --- | --- | --- | --- |
| (1) 150 | | For control of porcine colibacillosis (weanling pig scours) caused by susceptible strains of *Escherichia coli* | Feed as the sole ration for 14 consecutive days. Withdraw 28 days before slaughter | 058198 |
| (2) [Reserved] | | | | |

[[81 FR 94995](https://www.federalregister.gov/citation/81-FR-94995), Dec. 27, 2016, as amended at [87 FR 10970](https://www.federalregister.gov/citation/87-FR-10970), Feb. 28, 2022]
Editorial Note on Part 172
Editorial Note: Nomenclature changes to part 172 appear at 61 FR 14482, Apr. 2, 1996; 66 FR 56035, Nov. 6, 2001; 66 FR 66742, Dec. 27, 2001; 68 FR 15355, Mar. 31, 2003; 70 FR 40880, July 15, 2005; 70 FR 67651, Nov. 8, 2005; 70 FR 72074, Dec. 1, 2005; and 81 FR 49896, July 29, 2016.

§ 172.856 Propylene glycol mono- and diesters of fats and fatty acids. Propylene glycol mono- and diesters of fats and fatty acids may be safely used in food, subject to the following prescribed conditions: ( a ) They are produced from edible fats and/or fatty acids in compliance with § 172.860 and/or oleic acid derived from tall oil fatty acids in compliance with § 172.862.
( b ) They are used in food in amounts not in excess of that reasonably required to produce their intended effect.
**Exhibit 31(a)**
 **REPUBLIC BANCORP INC.**
 **Certification of the Principal Executive Officer**
 **Pursuant to 15 U.S.C. 78m(a) or 78o(d)**
 **(Section 302 of the Sarbanes-Oxley Act of 2002)**
 
 
 I, Dana M. Cluckey, certify that:
 
 1.
I have reviewed this quarterly report on Form 10-Q (for the quarterly period ended September 30, 2004) of Republic Bancorp Inc; 
 2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; 
 3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; 
 4.
The registrants other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and we have: 
 a)
designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; 
 b)
evaluated the effectiveness of the registrants disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and 
 c)
disclosed in this report any change in the registrants internal control over financial reporting that occurred during the registrants most recent fiscal quarter (the registrants fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrants internal control over financial reporting; and 
 5.
The registrants other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrants auditors and the audit committee of the registrants board of directors (or persons performing the equivalent functions): 
 a)
all significant deficiencies and material weaknesses in the design or operation of internal controls over financial reporting which are reasonably likely to adversely affect the registrants ability to record, process, summarize and report financial information; and 
 b)
any fraud, whether or not material, that involves management or other employees who have a significant role in the registrants internal control over financial reporting. 
 
 
 Date: November 8, 2004
/s/ Dana M. CluckeyDana M. CluckeyPresident and Chief Executive Officer
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Department of Health and Human Services

###### Centers for Disease Control and Prevention

In accordance with Section 10(a)(2) of the Federal Advisory  Committee Act (Pub. L. 92-463), the Centers for Disease  Control and Prevention (CDC) announces the aforementioned meeting:

*Time and Date:*                         12 p.m.-2 p.m., May 3, 2010 (Closed).                    

*Place:*                         Teleconference.                    

*Status:*                         The meeting will be closed to the public in accordance with provisions set forth in Section 552b(c)(4) and (6), Title 5 U.S.C., and the Determination of the Director, Management Analysis and Services Office, CDC, pursuant to Public Law 92-463.                    

*Matters to be Discussed:*                         The meeting will include the initial review, discussion, and evaluation of applications received in response to “Impact of Japanese Encephalitis Vaccination in Cambodia, FOA CK10-003.”                    

*Contact Person for More Information:*                         Gregory Anderson, M.S., M.P.H., Scientific Review Officer, CDC, 1600 Clifton Road, NE., Mailstop E60, Atlanta, GA 30333, Telephone: (404) 498-2293.                    

                        The Director, Management Analysis and Services Office, has been delegated the authority to sign                         **Federal Register**                         notices pertaining to announcements of meetings and other committee management activities, for both CDC and the Agency for Toxic Substances and Disease Registry.                    

Dated: February 24, 2010.

Elaine L. Baker,

Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.

[FR Doc. 2010-4288 Filed 3-1-10; 8:45 am]

BILLING CODE 4163-18-P